ReviewNature reviews. Neurology2020
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke.
Review in Nature reviews. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- Machine Learning for Predicting Stroke Risk Stratification Using Multiomics Data: Systematic Review.Journal of medical Internet research · 2026Pooled it
- Biomarkers of post-stroke cognitive impairment-a systematic literature review.Frontiers in behavioral neuroscience · 2026Pooled it
- Prognostic value of the CALLY index for functional outcomes in acute ischemic stroke: a systematic review and exploratory quantitative synthesis.Frontiers in neurology · 2026Pooled it
- Novel functional insights into ischemic stroke biology provided by the first genome-wide association study of stroke in indigenous Africans.Genome medicine · 2024Pooled it
- Common Data Elements for Disorders of Consciousness: Recommendations from the Working Group on Biospecimens and Biomarkers.Neurocritical care · 2024Pooled it
- Metabolite signature in acute ischemic stroke thrombi: a systematic review.Journal of thrombosis and thrombolysis · 2023Pooled it
- Multi-Level Biomarkers for Early Diagnosis of Ischaemic Stroke: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Crosstalk between ferroptosis and chondrocytes in osteoarthritis: a systematic review ofFrontiers in immunology · 2023Pooled it
- In Vitro Oxygen Glucose Deprivation Model of Ischemic Stroke: A Proteomics-Driven Systems Biological Perspective.Molecular neurobiology · 2022Pooled it
- Multi-omics approaches for deciphering the complexity of traditional Chinese medicine syndromes in stroke: A systematic review.Frontiers in pharmacology · 2022Pooled it
- Plasma Metabolites Link Dietary Patterns to Stroke Risk.Annals of neurology · 2023Trial
- A roadmap towards clinical use of molecular biomarkers in acute ischaemic stroke.Nature reviews. Neurology · 2026Review
- Multimodal profiling of atherosclerosis: Protocol and pilot data for the AtherOMICS biobank.Science advances · 2026Article
- Clinical Utility of Circulating Biomarkers for Diagnosis and Prognosis of Acute Stroke in the Emergency Department: A Narrative Review from Current Evidence to Clinical Implementation.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Review
- Thrombus Metabolism-Based Molecular Subtyping for Prognostic Risk Stratification in Acute Ischemic Stroke: A Preliminary Study.CNS neuroscience & therapeutics · 2026Article
- Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation.Journal of clinical medicine · 2026Review
- Advances in metabolomics of biomarkers for ischemic stroke: From bench to clinic.Neural regeneration research · 2026Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite many years of research, no biomarkers for stroke are available to use in clinical practice. Progress in high-throughput technologies has provided new opportunities to understand the pathophysiology of this complex disease, and these studies have generated large amounts of data and information at different molecular levels. The integration of these multi-omics data means that thousands of proteins (proteomics), genes (genomics), RNAs (transcriptomics) and metabolites (metabolomics) can be studied simultaneously, revealing interaction networks between the molecular levels. Integrated analysis of multi-omics data will provide useful insight into stroke pathogenesis, identification of therapeutic targets and biomarker discovery. In this Review, we detail current knowledge on the pathology of stroke and the current status of biomarker research in stroke. We summarize how proteomics, metabolomics, transcriptomics and genomics are all contributing to the identification of new candidate biomarkers that could be developed and used in clinical stroke management.
Indexed as
Identifiers
32322099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.